Move Over Social Media...
Say ‘Hello’ to Personal Media


Over the last decade or two, social media in particular has contributed towards the ‘big data society’ on an industrial scale, feeding huge corporate data behemoths at our own personal expense.

The team behind AVATR believes this needs to change. We want to put the ‘personal’ back into personal data!

How? Thanks to the magic of artificial intelligence, we’re putting some really clever machine learning to good use, and we’re on the verge of helping individuals take back control of their own data.


What is AVATR?


AVATR® is the world’s first personal AI robot that enables a person to leverage their data and mobile device to create, own and share their digital profile in order to receive precision medical services in return.

Further down the road, AVATR's central goal is to help users make the most of  all their own data, and use it to discover meaningful experiences by directly connecting them with other users, businesses and services…on their own terms.

Best of all, each user’s AVATR is not only constantly learning and refining itself, but it is also stored locally on the user’s own device - so when we say ‘personal’, we mean it!

Magenta Background.png

How is AVATR being built?


We are bringing science and art together to create a unique digital experience that is intuitively synchronised (on a highly personalised level) with individual users’ behaviours, sentiments, preferences and future decisions.  


To date, we have:

Innovate UK Bubble.png


Innovate UK funding

Private Investment Bubble.png


private investment

Registered trade mark Bubble.png


trade mark

Two Patents Bubble.png

2 patents


Newton Fund Bubble.png


of Newton Funding


WITH NHC Singapore


Having built the AVATR technology, we will start our commercial deployment in Singapore, in collaboration with clinicians at the National Heart Centre. With direct access to clinicians and paying patients in 43 countries, we are currently hardening our technology and market offer in preparation for global scale-up. This includes commercial demonstrators planned for London, Rome, Sao Paulo and Shanghai. 




Currently our target market segment is precision medicine, with a focus on management of lifestyle-related conditions.   By 2020, 50% of global health care expenditures - about $4 trillion - will be spent on lifestyle conditions such as heart disease, stroke and diabetes.  With the global population of over 65 years old projected to increase by 8% by  2020, market demand will increase further. 


In the future, we also hope to explore opportunities in retail, leisure, education and finance.


Working in partnership with